Showing results (691-700 of 738) with videos related to

Sort By:
Pageof 74
Blood Cancer Journal|April 19, 2025
Risk of lymphoid malignancy associated with cancer predisposition genesNicholas J Boddicker, Raphael Mwangi, Dennis P Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.
Blood|June 5, 2014
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesEdgardo R Parrilla Castellar, Elaine S Jaffe, Jonathan W Said, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyHervé Ghesquieres, Susan L Slager, Fabrice Jardin, et al.
Blood|April 3, 2015
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphomaRebecca L Boddicker, N Sertac Kip, Xiaoming Xing, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Pageof 74